What is XTL Biopharmaceuticals Price-to-Operating-Cash-Flow?
As of today (2024-06-04), XTL Biopharmaceuticals's share price is ₪0.089.
XTL Biopharmaceuticals's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 was ₪0.00. Hence, XTL Biopharmaceuticals's Price-to-Operating-Cash-Flow Ratio for today is .
The historical rank and industry rank for XTL Biopharmaceuticals's Price-to-Operating-Cash-Flow or its related term are showing as below:
XTL Biopharmaceuticals's Cash Flow from Operations per share for the
three
months ended in Mar. 2024 was ₪0.00.
Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 was ₪0.00.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 5.90% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 2.60% per year.
During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 20.70% per year.
During the past 13 years, XTL Biopharmaceuticals's highest 3-Year average Operating Cash Flow per Share Growth Rate was 66.90% per year. The lowest was -107.10% per year. And the median was 18.45% per year.
XTL Biopharmaceuticals Price-to-Operating-Cash-Flow Historical Data
The historical data trend for XTL Biopharmaceuticals's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTL Biopharmaceuticals Price-to-Operating-Cash-Flow Chart
|
XTL Biopharmaceuticals Annual Data
|
|
Trend |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Price-to-Operating-Cash-Flow |
|
Get a 7-Day Free Trial
|
|
|
- |
- |
- |
- |
- |
|
XTL Biopharmaceuticals Quarterly Data
|
|
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
Mar24 |
| Price-to-Operating-Cash-Flow |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
- |
- |
- |
- |
- |
Competitive Comparison of XTL Biopharmaceuticals's Price-to-Operating-Cash-Flow
For the Biotechnology subindustry, XTL Biopharmaceuticals's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
XTL Biopharmaceuticals's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, XTL Biopharmaceuticals's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where XTL Biopharmaceuticals's Price-to-Operating-Cash-Flow falls into.
XTL Biopharmaceuticals Price-to-Operating-Cash-Flow Calculation
XTL Biopharmaceuticals's Price-to-Operating-Cash-Flow ratio for today is calculated as
| Price-to-Operating-Cash-Flow Ratio | = | Share Price | / | Cash Flow from Operations per share (TTM) |
| = | 0.089 | / | 0 |
| = | |
XTL Biopharmaceuticals's Share Price of today is ₪0.089.
XTL Biopharmaceuticals's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₪0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).
It can also be calculated from the numbers for the whole company:
XTL Biopharmaceuticals (XTAE:XTLB) Business Description
Traded in Other Exchanges
Address
5 Badner Street, P.O.Box 8241, Ramat Gan, ISR, 5218102
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.
XTL Biopharmaceuticals (XTAE:XTLB) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XTAE:XTLB has been successfully added to your